Calviri Scientists Find New Class of Biomarkers for Predicting Treatment Response in Cancer Patients

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

Calviri Scientists Find New Class of Biomarkers for Predicting Treatment Response in Cancer Patients

header-info

May, 25, 2023

Scientists studying various immune checkpoint inhibitor therapies in patients with advanced lung cancer have found that a new class of blood-based biomarkers— anti-frameshift peptide antibodies, or anti-FSP antibodies— could be developed into improved or orthogonal tests for predicting tumor responses to treatment.

Access the full article to read more here.